Enrolling less homogeneous patient groups in clinical trials while maintaining safety may lead to a more accurate description of a drug’s safety and efficacy, FDA officials wrote in an article published April 20 in the New England Journal of Medicine.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
